Datapoint: FDA Expands Cibinqo’s Atopic Dermatitis Approval

The FDA on Feb. 10 expanded Pfizer’s Cibinqo’s approved use in atopic dermatitis. Its use now includes patients age 12 to 18 with “with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable,” according to a Pfizer press release. For the treatment of atopic dermatitis, the JAK inhibitor currently holds covered or better status for 78% of all insured lives under the pharmacy benefit. About 22% of covered lives have preferred access to Cibinqo, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 2/15/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 18

Datapoint: Arcutis Scores New Indication for Zoryve

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 17

Datapoint: Blue Shield of California Adds New Weight Loss, Diabetes Programs to Digital Health Platform

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 16

Datapoint: Sanford, Marshfield Clinic to Merge

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today